Pharma IPR 2024

Pharma IPR 2024

In early March, Remfry & Sagar Partner RANJNA MEHTA-DUTT was at the Pharma IPR India Conference and spoke on a very topical issue – CURRENT TRENDS & JURISPRUDENCE IN PATENT OPPOSITION.

She analysed whether the procedure for filing pleadings and evidence in pre-grant opposition proceedings needed review, the impact the Patents (Amendment) Rules 2024 (then still in draft stage) would have on opposition proceedings and also the take of the judiciary on the patent opposition process.

The session was well-received and the takeaways were especially pertinent given that the patent amendment rules came into force a few days later.




As per the rules of the Bar Council of India, we are not permitted to solicit work or advertise in any manner. By proceeding further and clicking on “I Agree” below, the user acknowledges that the transmission, receipt or use of the information on our website does not tantamount to solicitation, advertisement, inducement or personal communication of any sort for and on behalf of the Firm so as to create an attorney-client relationship.

The information provided herein should not be interpreted as legal advice, for which the user must make independent inquiries. Whilst every effort has been taken to ensure the accuracy of the contents of this website, Remfry & Sagar disclaims all liability arising from reliance placed by the user or any other third party on the information contained therein.